A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23‐valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
Epistemonikos ID: d812ac4c3e1aa0b88ba5bdf4a14b2068dd316681
First added on: May 15, 2024